Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes  

作　　者：Hidekatsu Yanai Yoshinori Masui Reo Yoshikawa Junwa Kunimatsu Hiroshi Kaneko 

机构地区：[1]Department of Internal Medicine, Kohnodai Hospital, National Center for Global Health and Medicine [2]Department of Rheumatology, Kohnodai Hospital, National Center for Global Health and Medicine

出　　处：《World Journal of Diabetes》2010年第3期99-100,共2页世界糖尿病杂志（英文版）（电子版）

摘　　要：The addition of the dipeptidyl peptidase-4 (DDP-4) inhibitor has been reported to achieve greater improvements in glucose metabolism with fewer adverse events compared to increasing the metformin dose in type 2 diabetic patients. We present a patient with steroid-induced diabetes whose blood glucose levels were ameliorated by the use of the DPP-4 inhibitor, showing that the DPP-4 inhibitors may be an effective and safe oral anti-diabetic drug for steroid-induced diabetes.The addition of the dipeptidyl peptidase-4 (DDP-4) inhibitor has been reported to achieve greater improvements in glucose metabolism with fewer adverse events compared to increasing the metformin dose in type 2 diabetic patients. We present a patient with steroid-induced diabetes whose blood glucose levels were ameliorated by the use of the DPP-4 inhibitor, showing that the DPP-4 inhibitors may be an effective and safe oral anti-diabetic drug for steroid-induced diabetes.

关 键 词：Dipeptidyl peptidase-4 NATEGLINIDE SITAGLIPTIN Steroid-induced DIABETES 

分 类 号：R587.1[医药卫生—内分泌]